{
  "trial_id": "NCT04858074",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Willing and able to give informed consent",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Age >30 years",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "Men and women with mild to moderate PD: Hoehn and Yahr scale stages 1 - 3",
      "label": "met",
      "evidence": ""
    }
  ],
  "exclusion": [
    {
      "criterion": "Subjects with advanced, severe disease, including those with dementia, severe osteoarthritis, allergies, stroke, and visual impairment.",
      "label": "not_met",
      "evidence": ""
    },
    {
      "criterion": "Presence of atypical PD syndromes due to drugs (e.g., metoclopramide, flunarizine), metabolic identified neurogenetic disorders (e.g., Wilson's disease), encephalitis, or other degenerative diseases (e.g., progressive supranuclear palsy).",
      "label": "not_met",
      "evidence": ""
    }
  ],
  "notes": "",
  "_meta": {
    "topic_id": "55",
    "trial_id": "NCT04858074",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}